Talon Resources Targets Ontario Gold Growth After AIM Move and Eagle Lake Acquisition, CEO Says. Watch here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksABC.L Regulatory News (ABC)

  • There is currently no data for ABC

Director/PDMR Shareholding

18 Mar 2013 16:41

RNS Number : 2782A
ABCAM Plc
18 March 2013
 

For immediate release

18 March 2013

 

ABCAM PLC

("Abcam" or "the Company")

Director's dealings

Cambridge, UK: Abcam plc (AIM: ABC), a global leader in the supply of protein research tools, has today been notified that on 15 March 2013, Jonathan Milner, a Director of the Company, transferred 75,000 Ordinary Shares of 0.2 pence each in the Company ("Ordinary Shares") for nil consideration to a charitable trust of which he is a trustee.

 

Following this transfer, Dr Milner's total interest in the Company is 28,229,124 Ordinary Shares of 0.2 pence each, representing approximately 14.2% of the Company's issued share capital. The total interest is constituted as follows:

 

Beneficial Interest

 

27,857,469

Non-Beneficial Interest:

371,655

 

For further information please contact:

Abcam

+ 44 (0) 1223 696 000

Jeff Iliffe, Chief Financial Officer

 

Numis Securities - Nominated Adviser & Joint Broker

+ 44 (0) 20 7260 1000

Michael Meade - Nominated Adviser

James Black - Corporate Broking

 

Peel Hunt LLP - Joint Broker

+ 44 (0) 20 7418 8900

Andy Crossley - Corporate Broking

 

Buchanan

+ 44 (0) 20 7466 5000

Mark Court / Fiona Henson / Sophie Cowles

 

Notes for editors:

About Abcam plc

Abcam is a producer and distributor of high quality protein research tools. These tools enable life scientists to analyse components of living cells at the molecular level, which is essential in understanding health and disease.

Headquartered in Cambridge (UK), Abcam has subsidiary offices in Bristol (UK), Cambridge, MA (USA), Eugene, OR (USA), San Francisco, CA (USA), Tokyo (Japan), Hangzhou and Hong Kong (both in China), allowing it to serve a global customer base in over 130 countries. Abcam employs over 680 staff across its eight operating companies.

Abcam now has an online catalogue of over 106,000 products sourced from over 400 suppliers. The catalogue includes a growing range of non-primary antibody products such as secondaries, proteins, peptides, lysates, immunoassays and other kits. Products are available for life science research and distributed to academic and commercial users. A highly developed eCommerce platform, which includes regional websites for the Chinese and Japanese markets, allows customers to access up-to-date and detailed technical product data sheets at the Company's website www.abcam.com.

Abcam was admitted to AIM in November 2005 and trades under the ticker symbol ABC. The Company's vision is to be the world's leading life science tools company.

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
RDSQVLFFXXFZBBB
Date   Source Headline
7th Jun 20067:00 amRNSTrading Update
9th May 20067:02 amRNSCommercial Development Appt.
27th Mar 200612:06 pmRNSDirector/PDMR Shareholding
14th Feb 20067:01 amRNSInterim Results
31st Jan 20067:01 amRNSNotification of Results
22nd Dec 20054:08 pmRNSDirectors Shareholding
3rd Nov 20057:00 amRNSFirst Day of Dealings

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.